A brand new examine finds that sufferers taking Eli Lilly (NYSE: LLY)Mounjaro misplaced extra weight than these taking Novo Nordisk (NVO) Ozempic.
The examine analyzed the digital well being data of roughly 41,000 overweight or chubby sufferers taking these medicine and located After three months of use, the typical Mounjaro consumer misplaced 5.9% of their weight, whereas the typical Ozempic consumer misplaced 3.6%.
After six months of use, Mounjaro customers skilled a mean lack of 10.1%, whereas Ozempic customers skilled a mean lack of 5.8%. Mounjaro customers skilled a mean weight lack of 15.3% at 12 months, in contrast with 8.3% for these utilizing Ozempic. The danger of gastrointestinal hostile occasions is analogous for each medicine.
The examine was printed Monday in JAMA Inner Medication.
Mounjaro’s lively ingredient is tezepatide, whereas Ozempic’s lively ingredient is semaglutide. Eli Lilly sells zeparatide as Mounjaro for the remedy of diabetes and Zepbound for weight reduction.
Likewise, Novo markets semaglutide for diabetes (known as Ozempic) and semaglutide for weight reduction (known as Wegovy).
Tezepatide and semaglutide each belong to a category of medicine known as GLP-1.